Bluevac is key in controlling the bluetongue virus (serotypes 1, 3, 4 and 8) in sheep and cattle. Its active immunization is crucial to combating the spread of the disease to new locations.
Line of inactivated vaccines to prevent and control the disease caused by the bluetongue virus (serotypes 1, 4, and 8) in sheep and cattle.
BLUEVAC-3
Inactivated vaccine to prevent and control the disease caused by the bluetongue virus serotype 3 in sheep and cattle.
BLUEVAC MULTISTRAIN
Line of inactivated vaccines to prevent and control the disease caused by several bluetongue virus serotypes (1+4, 4+8, and 1+8) in sheep and cattle.
Widely tested bluetongue vaccine
More than 230 million doses of Bluevac have been administered in Europe, which shows that Bluevac vaccination is a valuable tool for preventing the disease and one of the best options to reduce clinical signs and viremia in sheep and cattle herds.
Advanced adjuvant technology
Bluevac uses aluminum hydroxide and Quil-A as adjuvants. Quil-A is a purified derivate of saponin that blocks viral antigens and slows them down so they can be trapped by the vaccinated animal’s immune cells.
Benefits of vaccinating with Bluevac
01
Fewer local reactions
Bluevac doesn’t trigger serious local reactions.
02
Prevents viremia
No viral genome present after vaccination.
03
Proven effective
Widely tested and validated with RT-PCR testing.
04
Controls and decreases clinical cases
Reduces symptoms in sheep livestock.
05
Good benefit-cost ratio
The cost of a dose is very low compared to the losses due to infections with clinical signs and decreased yield and fertility.
06
Controls the spread of the disease
Decreases the spread to healthy animals, lowering the prevalence of the disease in endemic zones.
07
Decreased commercial restrictions
There are fewer restrictions on mobility of vaccinated animals between regions and countries.
08
Strong, lightweight packaging
The flexible plastic bottle doesn’t require ventilated extraction equipment.